GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » ROC %

Cryofocus Medtech (Shanghai) Co (HKSE:06922) ROC % : -123.30% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cryofocus Medtech (Shanghai) Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -123.30%.

As of today (2025-01-18), Cryofocus Medtech (Shanghai) Co's WACC % is 10.69%. Cryofocus Medtech (Shanghai) Co's ROC % is -130.84% (calculated using TTM income statement data). Cryofocus Medtech (Shanghai) Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cryofocus Medtech (Shanghai) Co ROC % Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co ROC % Chart

Cryofocus Medtech (Shanghai) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC %
-416.84 -262.74 -171.50 -131.78

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC % Get a 7-Day Free Trial -146.63 -199.89 -132.78 -138.12 -123.30

Cryofocus Medtech (Shanghai) Co ROC % Calculation

Cryofocus Medtech (Shanghai) Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-117.851 * ( 1 - 0% )/( (83.498 + 95.361)/ 2 )
=-117.851/89.4295
=-131.78 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=350.495 - 23.024 - ( 252.849 - max(0, 51.072 - 295.045+252.849))
=83.498

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=232.779 - 24.241 - ( 113.177 - max(0, 33.669 - 163.974+113.177))
=95.361

Cryofocus Medtech (Shanghai) Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-121.74 * ( 1 - 0% )/( (95.361 + 102.116)/ 2 )
=-121.74/98.7385
=-123.30 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=232.779 - 24.241 - ( 113.177 - max(0, 33.669 - 163.974+113.177))
=95.361

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryofocus Medtech (Shanghai) Co  (HKSE:06922) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cryofocus Medtech (Shanghai) Co's WACC % is 10.69%. Cryofocus Medtech (Shanghai) Co's ROC % is -130.84% (calculated using TTM income statement data). Cryofocus Medtech (Shanghai) Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cryofocus Medtech (Shanghai) Co ROC % Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryofocus Medtech (Shanghai) Co Business Description

Traded in Other Exchanges
N/A
Address
Lane 3399, Kangxin Road, Building 15, Pudong New Area, Shanghai, CHN, 200120
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products. The products offered by the company include; Bladder Cryoablation System, Pulmonary Nodule Localization Needle, and Endoscopic Clip for Anastomosis among others. Geographically, the company's revenue is generated from the sale of medical consumables and devices in the Chinese Mainland.
Executives
Wu Jianhui 2101 Beneficial owner
Li Hui 2202 Interest of your spouse
Lv Shiwen 2103 Interests held jointly with another person
Sun Xiaolu 2201 Interest of corporation controlled by you
Zhang Qian
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi He Huo Qi Ye You Xian He Huo
Shang Hai Shi Di Sheng Wu Ke Ji You Xian Gong Si
Shang Hai Bi Lin Xing Zi Chan Guan Li You Xian Gong Si
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Ning Bo Lin Feng Sheng Wu Ke Ji You Xian Gong Si
Shang Hai Shi Di Shi Ye Fa Zhan You Xian Gong Si
Sheng Shan Zi Chan Guan Li Shang Hai You Xian Gong Si
Gan Shi Xiong
Su Zhou Gong Ye Yuan Qu Zhi Nuo Shang Wu Xin Xi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Xin Jian Yuan Er Qi Chuang Ye Tou Zi Qi Ye You Xian He Huo 2101 Beneficial owner

Cryofocus Medtech (Shanghai) Co Headlines

No Headlines